3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
361
Precursor Cell Lymphoblastic Leukemia-Lymphoma
328
Lymphoma
297
Leukemia
254
Multiple Myeloma
246
Leukemia, Myeloid, Acute
241
Lymphoma, Non-Hodgkin
240
Lymphoma, Large B-Cell, Diffuse
238
Leukemia, Lymphocytic, Chronic, B-Cell
220
Myelodysplastic Syndromes
184
Lymphoma, Follicular
176
Hodgkin Disease
165
Lymphoma, Mantle-Cell
163
Burkitt Lymphoma
160
Lymphoma, B-Cell, Marginal Zone
117
Recurrence
115
Lymphoma, Large-Cell, Immunoblastic
95
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
82
Myeloproliferative Disorders
81
Melanoma
78
Neoplasms, Plasma Cell
77
Leukemia, Myeloid, Chronic-Phase
72
Hematologic Neoplasms
72
Leukemia, Myeloid, Accelerated Phase
71
Leukemia, Myelomonocytic, Chronic
69
Lymphoma, B-Cell
65
Dendritic Cell Sarcoma, Interdigitating
64
Triple Negative Breast Neoplasms
63
Ovarian Neoplasms
61
Congenital Abnormalities
59
Interventions
Fulvestrant
6
olaparib
4
Letrozole
4
trastuzumab deruxtecan
3
Aromatase Inhibitors
3
Anastrozole
3
sacituzumab govitecan
2
pyrotinib
2
eribulin
2
dalpiciclib
2
Paclitaxel
2
Goserelin
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Capecitabine
2
toripalimab
1
talazoparib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
elacestrant
1
disitamab vedotin
1
ceralasertib
1
capivasertib
1
balixafortide
1
apatinib
1
abemaciclib
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Breast Cancer
×
Cyclophosphamide
×
Clear all
NCT04304352
2023-06-28
VEX
European Institute of Oncology
Phase 2
Unknown
162 enrolled